Floatz logo

186 assets in Her2-Receptor Negative Breast Cancer

Therapeutic assets addressing Her2-Receptor Negative Breast Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
js207
Her2-Receptor Negative Breast Cancer
Fudan UniversityP2CCC (48)
Jskn003
Her2-Receptor Negative Breast Cancer
Fudan UniversityP2CCC (48)
Ladiratuzumab Vedotin
Her2-Receptor Negative Breast Cancer
QuantumLeap Healthcare CollaborativeP2CCC (48)
Lasofoxifene
Her2-Receptor Negative Breast Cancer
QuantumLeap Healthcare CollaborativeP2CCC (48)
Mitoxantrone
Her2-Receptor Negative Breast Cancer
Fudan UniversityP2CCC (48)
Neratinib
Her2-Receptor Negative Breast Cancer
Massachusetts General HospitalP2CCC (48)
Omega-N-Methylarginine
Her2-Receptor Negative Breast Cancer
The Methodist Hospital Research InstituteP2CCC (48)
PCS6422
Her2-Receptor Negative Breast Cancer
Processa PharmaceuticalsP2CCC (48)
Pexidartinib
Her2-Receptor Negative Breast Cancer
QuantumLeap Healthcare CollaborativeP2CCC (48)
Piflufolastat
Her2-Receptor Negative Breast Cancer
University of Wisconsin, MadisonP2CCC (48)
Pyrotinib
Her2-Receptor Negative Breast Cancer
Fudan UniversityP2CCC (48)
Rilvegostomig
Her2-Receptor Negative Breast Cancer
QuantumLeap Healthcare CollaborativeP2CCC (48)
Sacituzumab Tirumotecan
Her2-Receptor Negative Breast Cancer
Fudan UniversityP2CCC (48)
Sarilumab
Her2-Receptor Negative Breast Cancer
QuantumLeap Healthcare CollaborativeP2CCC (48)
Shr-1167
Her2-Receptor Negative Breast Cancer
Fudan UniversityP2CCC (48)
Shr-4602
Her2-Receptor Negative Breast Cancer
Fudan UniversityP2CCC (48)
Shr-6209
Her2-Receptor Negative Breast Cancer
Fudan UniversityP2CCC (48)
Shr-A1921
Her2-Receptor Negative Breast Cancer
Fudan UniversityP2CCC (48)
Shr-A2009
Her2-Receptor Negative Breast Cancer
Fudan UniversityP2CCC (48)
Shr-A2102
Her2-Receptor Negative Breast Cancer
Fudan UniversityP2CCC (48)
Sorafenib
Her2-Receptor Negative Breast Cancer
Fudan UniversityP2CCC (48)
Tinengotinib
Her2-Receptor Negative Breast Cancer
TransThera Sciences (Nanjing), Inc.P1/2CCC (48)
Tirzepatide
Her2-Receptor Negative Breast Cancer
Rutgers, The State University of New JerseyP2CCC (48)
Toripalimab
Her2-Receptor Negative Breast Cancer
Zhejiang Cancer HospitalP2CCC (48)
tqb2102
Her2-Receptor Negative Breast Cancer
Fudan UniversityP2CCC (48)
tqb2868
Her2-Receptor Negative Breast Cancer
Fudan UniversityP2CCC (48)
Trastuzumab Duocarmazine
Her2-Receptor Negative Breast Cancer
QuantumLeap Healthcare CollaborativeP2CCC (48)
Trebananib
Her2-Receptor Negative Breast Cancer
QuantumLeap Healthcare CollaborativeP2CCC (48)
Trilaciclib
Her2-Receptor Negative Breast Cancer
QuantumLeap Healthcare CollaborativeP2CCC (48)
utd1
Her2-Receptor Negative Breast Cancer
Hunan Cancer HospitalP1/2CCC (48)
Vepdegestrant
Her2-Receptor Negative Breast Cancer
QuantumLeap Healthcare CollaborativeP2CCC (48)
vv1
Her2-Receptor Negative Breast Cancer
QuantumLeap Healthcare CollaborativeP2CCC (48)
Ganetespib
Her2-Receptor Negative Breast Cancer
QuantumLeap Healthcare CollaborativeP2CC (47)
INX315
Her2-Receptor Negative Breast Cancer
Incyclix BioP1/2CC (47)
Naxitamab
Her2-Receptor Negative Breast Cancer
Margaret Gatti-MaysP1/2CC (47)
Universal Donor Expanded Tgf-Beta-Imprinted Nk Cells
Her2-Receptor Negative Breast Cancer
Margaret Gatti-MaysP1/2CC (47)
Nelitolimod
Her2-Receptor Negative Breast Cancer
QuantumLeap Healthcare CollaborativeP2CC (46)
Immunoglobulin G, Anti-(Human Insulin-Like Growth Factor I Receptor) (Human Monoclonal Heavy Chain), Disulfide With Human Monoclonal Light Chain, Dimer
Her2-Receptor Negative Breast Cancer
QuantumLeap Healthcare CollaborativeP2CC (45)
N-Desmethyl-4-Hydroxytamoxifen
Her2-Receptor Negative Breast Cancer
Atossa Therapeutics, Inc.P2CC (45)
Immunoglobulin G1, Anti-(Human Neuregulin Receptor Her3) (Human Monoclonal U3-1287 Heavy Chain), Disulfide With Human Monoclonal U3-1287 ?-Chain, Dimer
Her2-Receptor Negative Breast Cancer
QuantumLeap Healthcare CollaborativeP2CC (44)
Onapristone
Her2-Receptor Negative Breast Cancer
University of Wisconsin, MadisonP2CC (44)
Berzosertib
Her2-Receptor Negative Breast Cancer
National Cancer Institute (NCI)P1CC (43)
Felmetatug Vedotin
Her2-Receptor Negative Breast Cancer
Seagen, a wholly owned subsidiary of PfizerP1CC (43)
hs-10502
Her2-Receptor Negative Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.P1CC (43)
hs-20089
Her2-Receptor Negative Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.P1CC (43)
hs-20093
Her2-Receptor Negative Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.P1CC (43)
Leflunomide
Her2-Receptor Negative Breast Cancer
Deborah DoroshowP1CC (43)
Mesothelin-Targeted T Cells
Her2-Receptor Negative Breast Cancer
Memorial Sloan Kettering Cancer CenterP1CC (43)
Modified Vaccinia Virus Ankara Vaccine Expressing P53
Her2-Receptor Negative Breast Cancer
City of Hope Medical CenterP1CC (43)
nkt3447
Her2-Receptor Negative Breast Cancer
NiKang Therapeutics, Inc.P1CC (43)
Showing 101 to 150 of 186 assets
PreviousPage 3 of 4Next